Tirzepatide

About Tirzepatide

Tirzepatide mimics two gut hormones, GIP and GLP-1: it raises insulin release when blood sugar is high, lowers glucagon, slows stomach emptying and reduces appetite. Mounjaro is labeled, with diet and exercise, for blood sugar control in adults and, since December 2025, children 10 and older with type 2 diabetes, and since August 2026 to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk. Zepbound is labeled for weight loss and maintenance in adults with obesity, or overweight with a weight-related condition, and since December 2024 for moderate to severe obstructive sleep apnea in adults with obesity; it is not approved for children. Both start at 2.5 mg once a week and rise by 2.5 mg no sooner than every four weeks: Mounjaro to at most 15 mg (10 mg in children), Zepbound to 5, 10 or 15 mg (10 or 15 mg for sleep apnea).

The boxed warning: tirzepatide caused thyroid C-cell tumors in rats, it is not known whether it does in people, and it must not be used with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia type 2 (MEN 2). The labels also warn of pancreatitis, gallbladder disease, low blood sugar (especially with insulin or a sulfonylurea), kidney injury from dehydration, severe stomach and bowel reactions, allergic reactions, worsening diabetic eye disease, and inhaling stomach contents under anesthesia or deep sedation. Nausea, diarrhea, vomiting, constipation, indigestion and stomach pain are among the most common side effects.

Both labels now include a KwikPen (since January 2026) and a multi-dose vial, each holding four weekly doses, alongside single-dose pens and vials; a KwikPen is never shared, even with a new needle. Tirzepatide can make birth control pills less reliable, so a non-oral or added barrier method is used for four weeks after starting and after each dose increase. Zepbound is stopped when pregnancy is recognized, and Mounjaro is used in pregnancy only if the benefit justifies the risk to the fetus. In February 2026 a warning about suicidal behavior and ideation was removed from the Zepbound label. As of October 2026 the FDA lists the tirzepatide shortage as resolved, and it says compounded drugs, compounded tirzepatide included, are not FDA-approved or reviewed for safety, effectiveness or quality.

Taking Tirzepatide

How to take it

Once a week, at any time of day, with or without food, under the skin of the abdomen, thigh or upper arm, rotating sites with each dose. The day can be changed if doses stay at least 3 days apart.

If you miss a dose

Take it within 4 days of the missed dose; if more than 4 days have passed, skip it and take the next dose on your usual day. Never take two doses within 3 days of each other.

Storage

In the original carton away from light, never frozen. Single-dose pens and vials are refrigerated but may be kept at up to 86°F for up to 21 days in total. Unopened KwikPens and multi-dose vials are refrigerated (or thrown away after 30 days at up to 86°F); once in use, either can be refrigerated or kept at up to 86°F, and is thrown away 30 days after first use or after four weekly doses, even if medicine is left.

Interactions to know about

Birth control pills may work less well; the label advises a non-oral or added barrier method for four weeks after starting and after each dose increase. Insulin or a sulfonylurea raises the risk of low blood sugar. Slower stomach emptying can affect other oral medicines, and the care team should know about it before surgery or sedation.

This summarizes the official prescribing information. Your prescriber’s and pharmacist’s instructions, and the leaflet that comes with your medicine, take priority.

Why the cash price for Tirzepatide differs from pharmacy to pharmacy

Tirzepatide is sold only as Mounjaro and Zepbound, with no approved generic, so every fill is priced as a brand. The two brands and their single-dose pens, KwikPens and vials are separate products, so compare quotes for the same one and confirm the pharmacy can supply it. A single-dose pen or vial is one weekly dose, while a KwikPen or multi-dose vial holds four, and vials need a new syringe and needle for every dose.

Ways to pay less for Tirzepatide without insurance

• Make sure the prescription names the brand and presentation you will use (pen, KwikPen or vial), since the pharmacy can fill only what is written.
• Ask the maker whether a self-pay or savings program applies to someone paying cash; many copay cards require commercial insurance.
• Once your dose is stable, ask whether the prescription can cover more than one month, and compare more than one pharmacy.
• Upload the prescription to Script Unlock so licensed pharmacies can quote their cash price. You pay the pharmacy directly.

Questions to ask your pharmacist about Tirzepatide

1. 1.Is this Mounjaro or Zepbound, in the presentation and strength on my prescription?
2. 2.How long can my pen, KwikPen or vial stay out of the refrigerator?
3. 3.What should I use for birth control while my dose is being raised?
4. 4.Do my insulin or sulfonylurea doses need to change?

Related medications